Prof. Robert H. Grubbs, CaltecRobert H. Grubbs received his B.S. and M.S. Chemistry from the University of Florida at Gainesville in 1963 and 1965. Ph.D., Chemistry, from Columbia University, New York, in 1968. NIH Postdoctoral Fellow, Chemistry, Stanford University, 1968-69. He is now the Victor and Elizabeth Atkins Professor of Chemistry at the California Institute of Technology, Pasadena, California, and faculty member since 1978. He was a faculty member at Michigan State University from 1969 to 1978.
The Grubbs group discovers new catalysts and studies their fundamental chemistry and applications. For example, a family of catalysts for the interconversion of olefins, the olefin metathesis reaction has been discovered in the Grubbs laboratory. In addition to their broad usage in academic research, these catalysts are now used commercially. He has also been involved in the translation of technology through the founding of five companies.
In 2005, Robert H. Grubbs was awarded the Nobel Prize in Chemisrty jointly with Yves Chauvin and Richard R. Schrock for “the development of the metathesis method in organic synthesis."
https://grubbsgroup.caltech.edu

Prof. Christophe Copéret, ETH Zürich

Lecture Topic: Learning from Single-Site Catalysis and NMR Spectroscopy

Prof. Christophe Copéret was trained in chemistry and chemical engineering at the École Supérieure de Chimie Physique Électronique (CPE) de Lyon. He received a PhD in chemistry from Purdue University in 1996, for his research on the synthesis of complex molecules via Pd-catalyzed carbonylation reactions, supervised by Prof. E. Negishi.
After a postdoctoral stay with Prof. K.B. Sharpless at the Scripps Research Institute, Christophe was offered a research position at CNRS in 1998 and was promoted to Research Director in 2008. Since 2010, he is a Professor at the Department of Chemistry and Applied Biosciences of ETH Zürich.
His scientific interest lies at the frontiers of molecular, material and surface chemistry as well as NMR spectroscopy with the aims to design molecularly-defined solid catalysts through detailed mechanistic studies and structure-activity relationships.
http://www.coperetgroup.ethz.ch

Prof. Eva Hevia, University of Bern

Eva Hevia received both, her MSci degree in Chemistry and her Ph.D. degree, from the Universidad de Oviedo (Spain) in 1998 and 2002 respectively. Her doctoral studies were under the supervision of Professor Victor Riera and Dr Julio Perez.
In 2006, after a three-year appointment at the University of Strathclyde working as a Marie Curie Fellow with Professor Robert Mulvey, she took up a Royal Society University Research Fellowship and Lectureship at the same institution. Subsequently, she was promoted to Senior Lecturer in 2010, Reader in 2011, and to Professor in 2013. In 2019, Eva moved to the University of Bern where she is currently a Professor in Inorganic Chemistry.
Eva’s research interests include applying polar organometallic reagents incorporating cooperative effects to key organic transformations, as well as developing s-block-based metal catalysts.
http://evaheviagroup.com 
 

Prof. Anat Milo, Ben Gurion University

Anat Milo received her B.Sc./B.A. in Chemistry and Humanities from the Hebrew University of Jerusalem in 2001, M.Sc. from UPMC Paris in 2004, and Ph.D. from the Weizmann Institute of Science in 2011. Her postdoctoral studies at the University of Utah focused on developing physical organic descriptors and data analysis approaches for chemical reactions.
In October 2015, she returned to Israel to join the Department of Chemistry at Ben-Gurion University, where her research group develops experimental, statistical, and computational strategies for identifying molecular design principles in catalysis.
https://anatmilo.com 

Prof. Todd Hyster, Princeton University

Lecture Topics: Photoenzymatic Catalysis” and “Merging Small Molecule Catalysis with Enzymes in Chemical Synthesis

Todd Hyster is native of Minnesota and did his undergraduate studies at the University of Minnesota. He obtained his Ph.D. from Colorado State University, where he worked under the mentorship of Prof. Tomislav Rovis. As a graduate student, Todd developed methods for preparing nitrogen-heterocycles using Rhodium-catalyzed C–H activation. As part of this work, he was a Marie Curie Fellow in the labs of Tom Ward at the University of Basel, where he developed an artificial metalloenzyme to catalyze an asymmetric C–H activation reaction.
After completing his graduate studies, he moved to Caltech as an NIH-Postdoctoral Fellow with Frances Arnold where he evolved cytochrome P450s to catalyze nitrene-transfer reactions. He started his independent career in 2015 at Princeton University where his group is using single electron transfer mechanisms to enable substrate promiscuous enzymes to catalyze non-natural free radical reactions.
https://www.hysterlab.com 

Josep (Pep) Cornella graduated in chemistry in 2008 from the University of Barcelona. After completing his MSc thesis, he moved to the United Kingdom to pursue doctoral studies in the group of Prof. Igor Larrosa (Queen Mary University, London). In 2012, Pep moved back to Catalunya, where he joined the group of Prof. Ruben Martin (ICIQ) as a Marie Curie Postdoctoral Fellow. There, he developed novel transformations involving Ni-catalyzed C–O bond activation and carbon dioxide insertion into organic molecules. In 2015, he obtained a Beatriu de Pinós Fellowship to join the group of Prof. Phil S. Baran at the Scripps Research Institute in La Jolla, California. During his time at Scripps, he worked on the discovery and implementation of new transformations based on the concept of “redox-active esters” as readily available partners for Ni- and Fe-catalyzed C–C bond forming reactions. In 2017, Pep was appointed as a Group Leader in the Department of Organometallic Chemistry at the Max-Planck-Institut für Kohlenforschung in Mülheim an der Ruhr to create and lead the Sustainable Catalysis Laboratory.

Dr. Edouard Godineau, Syngenta Crop Protection AG

Lecture Topic: Green & Sustainable Chemistry, the industry perspective

Edouard Godineau received his PhD from the University of Bordeaux in 2007, with Prof. Yannick Landais. After a post-doctoral stay with Prof. A. Fürstner at the Max-Planck-Istitut für Kohlenforschung in Mühlhein a.d.R, he joined Syngenta Crop Protection in 2009 as a process chemist.
Since 2014, he is leading the process chemistry group at Syngenta where is he is responsible to identify and design most cost-effective possible synthetic routes to new active ingredients. Edouard was appointed Syngenta Fellow in December 2019.
https://www.syngenta.com

Dr. Thomas Carl, Siegfried AG

Lecture Topic: From lab to plant; process performance through new technologies and data management

Thomas Carl studied chemistry at the Universities of Stuttgart (Germany) and Reading (UK). He was awarded a PhD degree by the University of Basel for his research on electron transport through DNA under the supervision of Prof. Bernd Giese.
After post-doctoral studies with Prof. K. Peter C. Vollhardt at the University of California Berkeley, he returned to Switzerland in 2009 to take a position at Ciba Specialty Chemicals as process chemist. He held different management positions in industry, and last year he joined Siegfried AG as Head of Process R&D and Scale-Up.
https://www.siegfried.ch

Dr. Markus Fischer, Merck Sigma Aldrich Production GmbH

Lecture Topic: Development of green industrial processes

Markus Fischer received his diploma in chemistry from the Ludwig-Maximilians-University Munich under the supervision of Prof. Dr. Paul Knochel. His doctoral studies focused on the development of light-harvesting materials for organic solar cells. He received his PhD from the University of Ulm under the mentorship of Prof. Dr. Peter Bäuerle.
After a research internship with Prof. Andrew Holmes at the Bio21 Institute in Melbourne, he started his career at Evonik industries in process development. Since 2011, he is working for Merck KGaA. After management positions in process development and production in Darmstadt, Germany, he is now head of process development and process safety at the Buchs site in Switzerland.
The main task of the department is the portfolio management of about 5.000 production processes and the development of novel, robust and cost effective processes for external customers and in-house products, mainly for the regulated market.
https://www.sigmaaldrich.com/switzerland-schweiz.html

Dr. Audrey Langlois, Novartis

Lecture Title: Application of Pd-catalyzed transformations in the manufacture of LSZ102, a selective estrogen receptor degrader

Audrey Langlois obtained her PhD in organic chemistry from the University of Geneva (Switzerland), where she worked on asymmetric catalysis in the group of Prof. E. Peter Kündig. In 2012, she moved to Harvard University (Cambridge, USA) to perform her post-doctoral studies in the group of Prof. Andy G. Myers, working on the design of a fully-synthetic route to macrolide antibiotics. Audrey returned to Switzerland in 2013 to start her career as a process chemist. First, at SpiroChem, an ETH-Zürich spin-off and since 2014 at Novartis within the Chemical and Analytical Development department. Over the past years, Audrey has supported several drug development projects, ranging from classical small molecules to new chemical modalities.
https://www.novartis.com

 Dr. Lucie Lovelle, Novartis

Lecture Title: The Development Journey of the Bruton’s Tyrosine Kinase Inhibitor LOU064 (remibrutinib)

Lucie Lovelle is a Fellow in the Chemical and Analytical Development organization of Novartis. Lucie earned her PhD in Organic Chemistry from the University of Montreal (Canada), where she worked, under the supervision of Prof. André B. Charette, on the diastereo- and enantioselective synthesis of 1,2,3-trisubstituted cyclopropanes. In 2010, she moved to ETH Zürich (Switzerland) to complete her post-doctoral studies in the group of Prof. Ryan Gilmour, leveraging from the gauche effect to design and synthesize various fluorinated organocatalysts. Lucie was recruited a year later by Janssen, pharmaceutical companies of Johnson & Johnson (Schaffhausen, Switzerland) to work on, among other projects, the development of bedaquiline, an approved marketed drug to treat multi-drug-resistant tuberculosis (MDR-TB). Since 2015, Lucie is working at Novartis in process research & development for drug candidates across indications and phases of clinical development.
https://www.novartis.com